PR Newswire Clinical TrialsOriginal article
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
Phase 3VK2735Positive
AI Analysis
Summary
Viking Therapeutics announces initiation of Phase 3 clinical program for oral VK2735 in obese adults, with SUNRISE-1 and SUNRISE-2 studies evaluating the drug in patients with and without Type 2 Diabetes.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Initiation of oral Phase 3 clinical program
Importance:6/10
Sentiment:
0.60
Phase 3obesitytype 2 diabetesoral formulationclinical trial initiation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 14, 2026 11:05 AM